会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS
    • 取代(芳基,杂芳基,芳基甲基或甲氧基)乙氧基化合物
    • WO1997024117A1
    • 1997-07-10
    • PCT/US1997000264
    • 1997-01-02
    • RHONE-POULENC RORER PHARMACEUTICALS INC.GRONEBERG, Robert, D.NEUENSCHWANDER, Kent, W.DJURIC, Stevan, W.MCGEEHAN, Gerard, M.BURNS, Christopher, J.CONDON, Steven, M.MORRISSETTE, Matthew, M.SALVINO, Joseph, M.SCOTESE, Anthony, C.ULLRICH, John, W.
    • RHONE-POULENC RORER PHARMACEUTICALS INC.
    • A61K31/19
    • C07D209/48C07C259/06C07C317/44C07C323/60C07C2601/08C07D215/14C07D317/56C07D317/62
    • This invention is directed to compounds of formula (I), wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. Compounds within the scope of the present invention may also inhibit an MMP, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting MMPs, such disease states involve tissue breakdown and those associated with a physiologically detrimental excess of TNF. The present invention is therefore also directed to the pharmaceutical use of the compounds, pharmaceutical compositions containing the compounds, intermediates leading thereto and methods for the preparation of the compounds and their intermediates.
    • 本发明涉及式(I)的化合物,其中变量如本文所述。 本发明范围内的化合物具有有用的性质,更具体地说是药物性质。 它们特别可用于抑制TNF治疗患有与生理有害过量的肿瘤坏死因子(TNF)相关的疾病状态的患者的生产或生理作用。 本发明范围内的化合物还抑制环AMP磷酸二酯酶,并且可用于治疗与通过抑制环AMP磷酸二酯酶调节的病理状况相关的疾病状态,所述疾病状态包括炎性和自身免疫性疾病,特别是IV型环AMP 磷酸二酯酶。 本发明范围内的化合物还可以抑制MMP,并且可用于治疗与通过抑制MMP调节的病理状况相关的疾病状态,这种疾病状态涉及组织分解以及与生理上有害的过量TNF相关的疾病状态。 因此,本发明还涉及化合物的药物用途,含有这些化合物的药物组合物,导致其的中间体以及制备化合物及其中间体的方法。